Elagib KE - Search Results

1

Iron control of erythroid microtubule cytoskeleton as a potential target in treatment of iron-restricted anemia.

Goldfarb AN, Freeman KC, Sahu RK, Elagib KE, Holy M, Arneja A, Polanowska-Grabowska R, Gru AA, White Z 3rd, Khalil S, Kerins MJ, Ooi A, Leitinger N, Luckey CJ, Delehanty LL. Goldfarb AN, et al. Among authors: elagib ke. Nat Commun. 2021 Mar 12;12(1):1645. doi: 10.1038/s41467-021-21938-2. Nat Commun. 2021. PMID: 33712594 Free PMC article.

2

Liver kinase B1 (LKB1) in murine erythroid progenitors modulates erythropoietin setpoint in association with maturation control.

White Z 3rd, Elagib KE, Gru AA, Goldfarb AN. White Z 3rd, et al. Among authors: elagib ke. Blood Cells Mol Dis. 2022 Nov;97:102688. doi: 10.1016/j.bcmd.2022.102688. Epub 2022 Jun 11. Blood Cells Mol Dis. 2022. PMID: 35717902 Free PMC article.

3

AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.

Choi Y, Elagib KE, Goldfarb AN. Choi Y, et al. Among authors: elagib ke. Crit Rev Eukaryot Gene Expr. 2005;15(3):207-16. doi: 10.1615/critreveukargeneexpr.v15.i3.30. Crit Rev Eukaryot Gene Expr. 2005. PMID: 16390317 Review.

4

Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.

Choi Y, Elagib KE, Delehanty LL, Goldfarb AN. Choi Y, et al. Among authors: elagib ke. Cancer Res. 2006 Mar 15;66(6):2990-6. doi: 10.1158/0008-5472.CAN-05-2944. Cancer Res. 2006. PMID: 16540647

5

RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation.

Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. Elagib KE, et al. Blood. 2003 Jun 1;101(11):4333-41. doi: 10.1182/blood-2002-09-2708. Epub 2003 Feb 6. Blood. 2003. PMID: 12576332 Free article.

6

Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2.

Elagib KE, Xiao M, Hussaini IM, Delehanty LL, Palmer LA, Racke FK, Birrer MJ, Ganapathy-Kanniappan S, McDevitt MA, Goldfarb AN. Elagib KE, et al. Mol Cell Biol. 2004 Sep;24(17):7779-94. doi: 10.1128/MCB.24.17.7779-7794.2004. Mol Cell Biol. 2004. PMID: 15314183 Free PMC article.

7

Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.

Elagib KE, Goldfarb AN. Elagib KE, et al. Cancer Lett. 2007 Jun 28;251(2):179-86. doi: 10.1016/j.canlet.2006.10.010. Epub 2006 Nov 27. Cancer Lett. 2007. PMID: 17125917 Free PMC article. Review.

8

Cyclic AMP signaling inhibits megakaryocytic differentiation by targeting transcription factor 3 (E2A) cyclin-dependent kinase inhibitor 1A (CDKN1A) transcriptional axis.

Rubinstein JD, Elagib KE, Goldfarb AN. Rubinstein JD, et al. Among authors: elagib ke. J Biol Chem. 2012 Jun 1;287(23):19207-15. doi: 10.1074/jbc.M112.366476. Epub 2012 Apr 17. J Biol Chem. 2012. PMID: 22514271 Free PMC article.

9

Calpain 2 activation of P-TEFb drives megakaryocyte morphogenesis and is disrupted by leukemogenic GATA1 mutation.

Elagib KE, Rubinstein JD, Delehanty LL, Ngoh VS, Greer PA, Li S, Lee JK, Li Z, Orkin SH, Mihaylov IS, Goldfarb AN. Elagib KE, et al. Dev Cell. 2013 Dec 23;27(6):607-20. doi: 10.1016/j.devcel.2013.11.013. Dev Cell. 2013. PMID: 24369834 Free PMC article.

10

Megakaryocytic irreversible P-TEFb activation.

Elagib KE, Goldfarb AN. Elagib KE, et al. Cell Cycle. 2014;13(12):1827-8. doi: 10.4161/cc.29324. Epub 2014 May 27. Cell Cycle. 2014. PMID: 24866976 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page